Early benefit assessment: Reviews and negotiations – Problems and conflicts

When the legislature created the Act on the Restructuring of the Pharmaceutical Market (AMNOG), it included difficult components in terms of a mandatory discount, price moratorium and early benefit assessment that directly and massively impact existing business models. Especially with the procedure of the early benefit assessment, it has established a process that is as complex as it is complicated, and in some places it is questionable from a methodological standpoint.

To facilitate an easier categorization of individual aspects of the procedure, we have developed an interactive information graphic in cooperation with ÄrzteZeitung that illustrates the process of the early benefit assessment, including the parties involved and the resulting problems and conflicts.

Start info graphic as an animation

Download info graphic as a PDF document